Notably, the presence of BRAFV600E, coupled with a GNAQ mutation (A>C, p.Q209P) and a PTEN frame-shift deletion, was linked to heightened AKT activity, supporting a promising, synergistic treatment combination capable of blocking tumor growth [71]. Here, AKT1 is linked to neoplasm.